SCIENCE AND STRATEGIC ADVISORY BOARD
The Science and Strategic Advisory Board (SSAB) was created to provide short and long-term business counsel and advise PHILTER™ on technical and strategic initiatives to expand the company’s impact on mitigating secondhand smoke. In conjunction with our research and development team, the SSAB will aid in continuing development and further our technology validation in the scientific community.
SCIENCE AND STRATEGIC ADVISORY BOARD
The Science and Strategic Advisory Board (SSAB) was created to provide short and long-term business counsel and advise PHILTER™ on technical and strategic initiatives to expand the company’s impact on mitigating secondhand smoke. In conjunction with our research and development team, the SSAB will aid in continuing development and further our technology validation in the scientific community.
TWO LEADING SCIENTISTS IN TOXICOLOGY AND REGULATORY AFFAIRS ARE ON THE SSAB
TWO LEADING SCIENTISTS IN TOXICOLOGY AND
REGULATORY AFFAIRS ARE ON THE SSAB
REGULATORY AFFAIRS ARE ON THE SSAB
Dr. Willie J. McKinney
Dr. Willie J. McKinney has held several roles with Altria and JUUL. In 1998 Dr. McKinney joined the Altria family of companies and held a number of academic and research roles before joining the Executive Leadership Team as Vice President of Regulatory Sciences. His time at Altria was followed by serving as Vice President of Global Regulatory Affairs for JUUL labs in San Francisco.
Dr. McKinney served on FDA’s Tobacco Product Scientific Advisory Committee (TPSAC). Board Certified as a Toxicologist by the American Board of Toxicology in 2004, Dr. McKinney holds a Ph.D., in Environmental Toxicology from the University of North Carolina at Chapel Hill, and M.S., in Biology, from North Carolina Central University, and a B.S., in Biology from Xavier University in New Orleans.
Dr. Michael S. Werley
Dr. Michael S. Werley spent over two decades at Philip Morris/Altria, most recently serving in the capacity of Principal Scientist. He has authored numerous research studies on tobacco, nicotine, toxicity, inhalation, exposure, and harm reduction.
Dr. Werley earned a Ph.D., in Pharmacology/Toxicology from Temple University School of Pharmacy and a Master of Science (MS) from Temple University School of Medicine.
Dr. Willie J. McKinney
Dr. Willie J. McKinney has held several roles with Altria and JUUL. In 1998 Dr. McKinney joined the Altria family of companies and held a number of academic and research roles before joining the Executive Leadership Team as Vice President of Regulatory Sciences. His time at Altria was followed by serving as Vice President of Global Regulatory Affairs for JUUL labs in San Francisco.
Dr. McKinney served on FDA’s Tobacco Product Scientific Advisory Committee (TPSAC). Board Certified as a Toxicologist by the American Board of Toxicology in 2004, Dr. McKinney holds a Ph.D., in Environmental Toxicology from the University of North Carolina at Chapel Hill, and M.S., in Biology, from North Carolina Central University, and a B.S., in Biology from Xavier University in New Orleans.
Dr. Michael S. Werley spent over two decades at Philip Morris/Altria, most recently serving in the capacity of Principal Scientist. He has authored numerous research studies on tobacco, nicotine, toxicity, inhalation, exposure, and harm reduction.
Dr. Werley earned a Ph.D., in Pharmacology/Toxicology from Temple University School of Pharmacy and a Master of Science (MS) from Temple University School of Medicine.
Dr. Michael S. Werley
I AM IMPRESSED WITH THE EXPERIENCE OF THE PHILTER™ TEAM, AND PARTICULARLY THEIR FILTRATION INNOVATIONS. They are in the right place at the right time with the right technology to address secondhand smoke emissions,” Dr. Willie McKinney said. “The opportunities to create safer vaping products is vast, and that gets me excited.
I AM IMPRESSED WITH THE EXPERIENCE OF THE PHILTER™ TEAM, AND PARTICULARLY THEIR FILTRATION INNOVATIONS. They are in the right place at the right time with the right technology to address secondhand smoke emissions,” Dr. Willie McKinney said. “The opportunities to create safer vaping products is vast, and that gets me excited.
RESULTS DRIVEN
With the goal of our work being applied to impactful social solutions, its imperative we build relationships with the scientific community. Working closely with advisors like Dr. McKinney and Dr. Werley expands our inhalation research and its effect on a person’s exhale. As our team continues to explore the efficiency of our technology on exhalant, how a person inhales is very much a part of the equation.
Especially as atomizers on vaporizers improve and distillates take on new ingredients, our ability to study inhalation through the research of our toxicologists will further improve the results of our products.
To further this research, PHILTER™ has filed a scientific abstract in in effort to publish papers as they relate to the current issue of second and third hand particulate and the harm reduction that our technology offers.
RESULTS DRIVEN
With the goal of our work being applied to impactful social solutions, its imperative we build relationships with the scientific community. Working closely with advisors like Dr. McKinney and Dr. Werley expands our inhalation research and its effect on a person’s exhale. As our team continues to explore the efficiency of our technology on exhalant, how a person inhales is very much a part of the equation.
Especially as atomizers on vaporizers improve and distillates take on new ingredients, our ability to study inhalation through the research of our toxicologists will further improve the results of our products.
To further this research, PHILTER™ has filed a scientific abstract in in effort to publish papers as they relate to the current issue of second and third hand particulate and the harm reduction that our technology offers.
David Paton
David Paton held senior roles in innovation and R&D with British American Tobacco (BAT) from 2010 until 2022 including being the Head of Product Development responsible for the design and launch of BAT’s heated tobacco product glo. Latterly, he created and led an open innovation organization within BAT responsible for advancing the company’s technology pipeline through engagement with start-up and scale-up companies globally.
Timothy Fitzwilliam began his career as a U.S. Navy Nuclear Engineer specializing in reactor controls and instrumentation. He later pursued his career in patent law and held partner level positions with several law firms in San Diego and Orange County, California. Timothy is expertise is analyzing new technology for claims drafting and/or protection utilizing a variety of IP mechanisms, negotiating with Patent Examiners with detailed, intricate knowledge of Title 37 of the Code of Federal Regulations and the Patent Cooperation Treaty (PCT).
Timothy Fitzwilliam
David Panton
David Paton held senior roles in innovation and R&D with British American Tobacco (BAT) from 2010 until 2022 including being the Head of Product Development responsible for the design and launch of BAT’s heated tobacco product glo. Latterly, he created and led an open innovation organization within BAT responsible for advancing the company’s technology pipeline through engagement with start-up and scale-up companies globally.
Timothy Fitzwilliam
Timothy Fitzwilliam began his career as a U.S. Navy Nuclear Engineer specializing in reactor controls and instrumentation. He later pursued his career in patent law and held partner level positions with several law firms in San Diego and Orange County, California. Timothy is expertise is analyzing new technology for claims drafting and/or protection utilizing a variety of IP mechanisms, negotiating with Patent Examiners with detailed, intricate knowledge of Title 37 of the Code of Federal Regulations and the Patent Cooperation Treaty (PCT).
PUBLIC POLICY ADVOCACY
PHILTER™ believes that the future of vaping and public consumption of cannabis will soon be under the scrutiny of the federal government. Conditioned to ban actitivities rather than find solutions, regulations could become strong headwinds as the cannabis industry works to normalize consumption.
Mitch Mulanix
Mitch Mulanix, a sought-after lobbyist, has a proven record of influencing government policy. Mitch leads the effort to stay abreast of the regulatory environment for the cannabis and nicotine industries.
PUBLIC POLICY ADVOCACY
PHILTER™ believes that the future of vaping and public consumption of cannabis will soon be under the scrutiny of the federal government. Conditioned to ban actitivities rather than find solutions, regulations could become strong headwinds as the cannabis industry works to normalize consumption.
Your Content Goes Here
Mitch Mulanix
Mitch Mulanix, a sought-after lobbyist, has a proven record of influencing government policy. Mitch leads the effort to stay abreast of the regulatory environment for the cannabis and nicotine industries.